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Cell cycle regulatory proteins in glomerular disease. Evidence mitosis and cytokinesis (cell division) in the M phase
is accumulating that directly responsible for the rate of progres- (Fig. 1).
sion of glomerular disease are specific positive (cyclins and Second, the original view that the cell cycle only gov-
cyclin-dependent kinases) and negative (cyclin-kinase inhibi- erns cell proliferation is no longer valid because under
tors) cell cycle regulatory proteins. The challenge for nephrolo-
certain circumstances, arrest in or exit from the cell cyclegists is to determine which ones are expressed in renal disease
results in different types of growth (Fig. 1). Thus, arrestand their precise role in glomerular cell proliferation, hypertro-
in G1 is associated with hypertrophy [3]. Exit from thephy and differentiation. Ultimately the goal is to find ever
cell cycle in late G1 leads to apoptosis [4], and the pro-more appropriate therapeutic strategies to arrest or prevent
progressive renal disease. grammed exit from the cell cycle at G2/M is associated
with cell differentiation [5].
Third, each phase of the cell cycle is controlled by
specific positive [cyclins and cyclin-dependent kinasesThere are many forms of glomerular growth that char-
(CDKs)] [6, 7] and negative (cyclin-kinase inhibitors) cell
acterize different types of glomerular diseases, and these
cycle regulatory proteins (Fig. 2) [8]. Detailed reviews of
include proliferation, hypertrophy, and differentiation. cell cycle proteins has been presented by others at this
As is discussed later in this article, each type of glomeru- symposium and in other reviews. In brief, progression
lar growth underlies the development of progressive glo- through or arrest during the cell cycle is controlled by
merulosclerosis, and thus, as nephrologists, it is of funda- cell cycle regulatory proteins. Proliferation (completion
mental importance that we understand and can intervene of the cell cycle) requires that cyclins bind to and activate
with these processes to reduce progressive disease. There specific CDKs in each phase of the cell cycle (Fig. 2).
are multiple potential mediators of glomerular growth, In contrast, the inhibition of cyclin-CDK complexes by
such as growth factors and their receptors, signaling path- cyclin-kinase inhibitors inhibits proliferation by causing
ways, and transcription factors. However, there is in- cell cycle arrest.
The study of cell cycle regulatory proteins in glomeru-creasing evidence to show that regulation of the cell cycle
lar disease poses a number of interesting challenges forby cell cycle regulatory proteins, which are predomi-
nephrologists. These include determining: (a) which spe-nantly located in the nucleus, ultimately determines the
cific cell cycle proteins are expressed in glomerular dis-growth response to injury.
ease; (b) the role of cell cycle proteins in glomerularOver the past decade, particularly the past few years,
cell proliferation, hypertrophy, and differentiation; (c)three paradigms have emerged in the study of the cell
whether or not these findings are specific to glomerularcycle. First, each phase of the cell cycle serves a specific
cells and how they differ from nonrenal cells; (d) adapt-function in preparing the cell to proliferate [1]. Thus, in
ing what has been learned in renal and nonrenal cell
G0 phase of the cell cycle, cells such as normal glomerular culture studies to experimental and human glomerular
cells are quiescent [2]. Proliferation requires that cells disease; and (e) satisfying the ultimate goal, which is to
engage the cell cycle at early G1 and progress through identify specific cell cycle proteins as therapeutic targets
and complete each phase of the cell cycle. In preparing in glomerular disease.
the cell to proliferate, protein synthesis increases in G1.
DNA synthesis occurs in the S phase, and cells undergo
MESANGIAL CELL PROLIFERATION
There is now abundant evidence to show that cell
proliferation is central to several types of glomerularKey words: glomerular growth, cell proliferation, hypertrophy, pro-
gressive glomerulosclerosis. diseases [9], thus making the potential to alter the prolif-
erative response of great interest to both clinical and 1999 by the International Society of Nephrology
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Fig. 1. Phases of the cell cycle. The cell cycle
is divided into the G0 (quiescent), S (DNA
synthesis), and M (mitosis) phases, which are
separated by the resting phases called G1 and
G2. Proliferation requires that cells progress
through the cell cycle. Arrest in G1 can result
in inhibition of proliferation or, under differ-
ent circumstances, hypertrophy. Exit from the
cell cycle in late G1 results in apoptosis,
whereas cells exit in G2 to undergo differentia-
tion.
Fig. 2. Cell cycle regulatory proteins. Progression through each phase of the cell cycle requires that the positive cell cycle proteins cyclins bind
to and activate a specific cyclin-dependent kinase (CDK). In contrast, proliferation is inhibited by negative cell cycle proteins called cyclin kinase
inhibitors. The INK4 inhibitors are restricted to G1 cyclin-CDK complexes, whereas the CIP/KIP inhibitors inhibit G1 and S phase cyclin-CDK
complexes.
experimental nephrologists. A characteristic response to lonephritis (Thy1 model) is induced by an antibody di-
rected against the Thy1 antigen normally present on ratimmune [IgA nephropathy, mesangial proliferative glo-
merulonephritis (MPGN), lupus nephritis] and nonim- mesangial cells, which results in a complement-depen-
dent injury to the mesangial cell (mesangiolysis) [19, 20].mune (remnant kidney)-mediated glomerular injury is
mesangial cell proliferation [10]. The importance of mes- This is followed by a phase of marked mesangial cell
proliferation, which precedes and is closely associatedangial cell proliferation has been shown in experimental
and human glomerular disease, where mesangial cell pro- with the development of matrix accumulation and a de-
cline in renal function [13]. The Thy1 model of mesangialliferation precedes and often predicts increased mesan-
gial matrix production [11]. Moreover, maneuvers that proliferative glomerulonephritis is therefore a very use-
ful model to further our understanding of the mecha-reduce mesangial cell proliferation such as low-protein
diet [12], complement depletion [13, 14], blocking the nisms underlying the mesangial cell’s proliferative re-
sponse to injury.cytokines platelet-derived growth factor (PDGF) [15],
basic fibroblast growth factor (bFGF), and heparin [16], The onset of mesangial cell proliferation in Thy1 glo-
merulonephritis is associated with a significant increaseinhibiting the PDGF receptor with trapidil [17], and in-
hibiting specific intracellular signaling pathways with in immunostaining for cyclin A [21]. The catalytic partner
of cyclin A is CDK2, which is required and essential forphosphodiesterase inhibitors [18] have also been associ-
ated with the reduction in mesangial matrix production. DNA synthesis [22, 23]. In contrast to quiescent nonrenal
cells where CDK2 is normally constitutively expressedHowever, we have focused on the role of cell cycle pro-
teins in mesangial cell proliferation because of the com- throughout the cell cycle, CDK2 immunostaining was
absent in the normal quiescent rat glomerulus [21]. How-pelling view that cell proliferation is ultimately con-
trolled in the nucleus by these proteins. ever, mesangial cell proliferation in experimental glo-
merulonephritis is associated with a marked increase
Cyclins and cyclin-dependent kinases in mesangial- in glomerular immunostaining for CDK2, and double
cell proliferation immunostaining with cell-specific markers showed that
CDK2 localizes to mesangial cells [21]. To show thatWe began our studies by examining the expression of
specific cell cycle proteins in experimental glomerular CDK2 was functionally active, glomeruli were isolated
from Thy1 animals, and protein was extracted to measuredisease. Experimental mesangial proliferative glomeru-
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CDK2 activity by the histone H1 kinase assay. Our data protein. Furthermore, decreasing CDK2 activity pro-
foundly inhibited glomerular cell proliferation, whichshowed that CDK2 activity was markedly increased dur-
ing mesangial cell proliferation in vivo [21]. In other was associated with an improvement in renal function.
With newer and more potent pharmacological agentsexperimental models associated with mesangial cell pro-
liferation such as the remnant kidney model [24], CDK2 being developed that target specific cell cycle proteins,
CDK2 should be considered as a potential therapeuticprotein is also increased. More recently, we have shown
that CDK2 immunostaining is also increased during the target for inflammatory diseases characterized by prolif-
eration.proliferative phase following endothelial cell injury in
experimental thrombotic microangiopathy (unpublished
Cyclin kinase inhibitors in glomerulardata). Moreover, CDK2 protein and activity are also
cell proliferationincreased during growth factor-induced mesangial cell
proliferation in vitro [25, 26]. Cyclin kinase inhibitors (CKIs) inhibit cell prolifera-
tion by binding to and inactivating specific cyclin-CDKShowing that both the expression and activity for
CDK2 were increased in experimental glomerulonephri- complexes [8, 30, 31]. There are two families of CKIs
that are based on sequence homology and the phase oftis suggested that this cell cycle protein may be a potential
target for therapeutic intervention in diseases character- the cell cycle in which they inhibit cyclin-CDK complexes
(Fig. 2). We have focused on the Cip/Kip family of CKIs,ized by mesangial cell proliferation. To this end, we stud-
ied the purine analogue roscovitine [27–29] and showed which includes p21, p27, and p57, because these CKIs
inhibit early G1 (d-type cyclin-CDK4, 6), late G1 (cyclinthat roscovitine causes a dose-dependent reduction in
CDK2 activity without altering CDK2 proteins levels E-CDK2), and S-phase (cyclin A-CDK2) cyclin-CDK
complexes. What has become increasingly evident is thatin cultured mesangial cells [26]. Furthermore, inhibiting
CDK2 activity by roscovitine completely abrogated the distribution and function of these CKIs are not pre-
dictable or expected and are cell-type specific. There isgrowth factor-induced mesangial cell proliferation in
vitro [26]. To determine the role of CDK2 in mesangial a differential expression of CKIs in the normal quiescent
glomerulus. Immunostaining for p21 is absent in normalcell proliferation in vivo, roscovitine was given as daily
intraperitoneal injections to Thy1 animals, which re- glomeruli, whereas p27 is constitutively expressed in all
three resident glomerular cell types [21]. In contrast,sulted in a significant reduction in the glomerular activity
for CDK2 compared with control animals. Importantly, immunostaining for p57Kip2 (p57) localizes exclusively to
glomerular epithelial cells (GECs; podocytes).roscovitine did not interfere with the binding of Thy1
antibody, complement activation, or the influx of infil- Similar to what has been shown in the mesangial cell
in vitro [32], mesangial cell proliferation in vivo in thetrating cells such as macrophages and platelets during
the early phase of inflammation. Our results showed that Thy1 model is associated with a marked decrease in
levels for p27 [32]. Moreover, by day 5, which is the peakthe early decrease in CDK2 activity was associated with
a marked reduction in the peak (day 5) of mesangial cell of mesangial cell proliferation in this model, p27 levels
are barely detectable. However, during the recoveryproliferation and glomerular cellularity in Thy1 neph-
ritis [26]. phase of mesangial cell injury, where proliferation
ceases, p27 levels returned to baseline. Of note is thatAs discussed earlier, previous studies have established
a relationship between mesangial cell proliferation and the decrease in levels of p27 during mesangial cell prolif-
eration was not a predictable finding because p27 levelsmatrix production [9]. Our results showed that the de-
crease in mesangial cell proliferation induced by roscovi- remain unchanged during proliferation in other cell types
such as vascular smooth muscle cells (M. Reidy, personaltine was also associated with a significant decrease in the
extracellular matrix proteins collagen type IV, laminin, communication).
In contrast to p27, there is de novo synthesis of theand fibronectin [26]. Moreover, renal function was sig-
nificantly improved compared with control animals. CKI p21Cip1,WAF1 (p21) during Thy1 glomerulonephritis,
and double immunostaining showed that p21 localizedWhat happens if CDK2 activity is inhibited once mesan-
gial cell proliferation has already been established rather to mesangial cells [32]. Furthermore, the increase in p21
expression coincided with the resolution phase of mesan-than prior to the onset of proliferation? To answer this,
Thy1 rats were given roscovitine starting at day 3 when gial cell proliferation in this model. Further studies are
being undertaken to determine whether this CKI is re-proliferating cell nuclear antigen and BrdU, markers
of DNA synthesis, were already increased. When given quired for the resolution of mesangial cell proliferation
in disease.under these conditions, roscovitine also significantly re-
duced mesangial cell proliferation at later time points in We have used a genetic approach to establish the func-
tional role of p27 in glomerular cell proliferation. Experi-Thy1 [26].
These studies demonstrated that CDK2 activity could mental glomerulonephritis was induced in p27 wild-type
(1/1) and p27 knockout (2/2) mice [33], and the studybe inhibited in vivo without altering the level of the
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cell proliferation requires an increase in expression and
activity of the positive cell cycle proteins cyclin A-CDK2.
However, the onset and magnitude of mesangial cell
proliferation are determined by the CKI p27, which sup-
ports the idea that p27 sets the threshold at which prolif-
eration occurs.
VISCERAL GLOMERULAR EPITHELIAL CELL
PROLIFERATION AND DIFFERENTIATION
Glomerular epithelial cells exit the cell cycle
during glomerulogenesis
The mature visceral GEC or podocyte is a unique
glomerular cell because its growth response to injury
differs from the mesangial and endothelial cells by virtue
of its apparent inability to proliferate [34]. However, in
contrast to mature GECs, immature GECs proliferate
during specific stages of glomerulogenesis [35]. Thus,
during the S-shaped stage, undifferentiated glomerular
cells that transform into GECs are characterized by
marked proliferation. However, during the comma stage
of glomerular development, GECs exit the cell cycle and
become terminally differentiated (Fig. 1), a phenotype
that is quiescent.
Fig. 3. Mesangial cell proliferation. The onset of mesangial cell prolif- We speculated that the GEC exit from the cell cycle
eration requires increased expression and activity of cyclin A-CDK2. during glomerulogenesis was due to specific CKIs. To
The levels of the cyclin kinase inhibitor p27 determine the proliferative
test this hypothesis, we studied human glomerulogenesisthreshold so that proliferation is augmented when p27 levels decrease.
The resolution of proliferation requires a decrease in CDK2 activity, in which both proliferating and nonproliferating cell pop-
which may be due to a decrease in cyclin A and CDK2 expression and/ ulations can easily be identified in the same kidney. Im-
or an increase in levels of the p21 and p27.
munostaining for the CKI p27 was absent in proliferating
immature cells that become GECs during the S-shaped
stage of glomerular development. In contrast, the cessa-
showed three findings. First, under normal physiological tion of GEC proliferation that accompanies GEC exit
conditions, the loss of p27 by itself was not associated from the cell cycle coincided with the de novo expression
with ongoing DNA synthesis in adolescent p272/2 of p27 [36]. These results suggest that p27 may be re-
mouse kidneys. Second, during inflammatory glomerulo- quired for normal GEC differentiation.
nephritis, the onset of glomerular cell DNA synthesis and What about the expression of other CKIs during GEC
proliferation occurred at earlier time points in p272/2 development? p57 is also expressed de novo in GECs
mice compared with controls. Third, in glomerulonephri- during mouse and rat glomerulogenesis. A role for p57 in
tis, the magnitude of glomerular DNA synthesis and GEC biology has been shown in genetic studies. Animals
proliferation was markedly increased at all time points
that lack p57 (p57 knockout mice) are born with fusedstudied in p272/2 mice compared with controls. To en-
foot processes and have many features that resemblesure that the increase in glomerular cell proliferation in
Beckwith–Wederman syndrome [37]. These studies sug-p272/2 mice was not due to a difference in immune-
gest that p57 may be required for normal GEC develop-response, p271/1 and p272/2 mice underwent total
ment. In contrast, mice lacking the CKI p21 (p272/2body irradiation, and the bone marrow was reconstituted
mice) have normal kidneys, suggesting that p21 is notwith marrow from normal p271/1 mice. Experimental
essential for normal GEC differentiation. Taken to-glomerulonephritis was then induced in both groups of
gether, specific CKIs may be essential for the develop-marrow-transplanted mice. The results confirmed that
ment of the quiescent differentiated GEC phenotype.glomerular cell proliferation was increased in nephritic
p272/2 mice compared with controls, and also demon-
Inability of mature differentiated glomerular epithelialstrated that the levels of p27 in the glomerulus rather
cell proliferationthan the immune response determine the proliferative
Although there is some debate regarding the prolifera-response to injury.
tive capacity of mature GECs, most studies have shownA summary of the role for cell cycle proteins in mesan-
gial cell proliferation is shown in Figure 3. Mesangial that in striking contrast to mesangial and endothelial
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cells, GEC proliferation is not marked. However, under of both p21 and p27 to cyclin A-CDK2 complexes in
PHN rats compared with controls. Moreover, p21 andcertain circumstances, GECs do re-enter the cell cycle
and undergo DNA synthesis, albeit low grade compared p27 inhibited the activity of CDK2 and thereby limited
DNA synthesis [45].with mesangial cells, and proliferate [38]. However, the
current paradigm is that the relative inability of the The cytokine basic fibroblast growth factor (bFGF) is
a mitogen for GECs in vitro [46], and giving bFGF toGECs to proliferate may underlie the development of
glomerular sclerosis in many forms of injury to the GECs passive Heyman’s nephritis (PHN) rats increases DNA
synthesis in GECs [47]. To determine if the increase in[34, 39, 40].
Many differentiated cells can re-engage the cell cycle GEC DNA synthesis was due to an increase in positive
cell cycle proteins or a decrease in negative cell cycleunder certain cues. Why then do mature GECs not prolif-
erate? One thesis is that terminally differentiated GECs proteins, bFGF was given to PHN rats [45]. The expres-
sion for CDK2 was not altered by bFGF. However, bFGFlack certain positive cell cycle (cyclins and CDKs) pro-
teins required to progress through the cell cycle. Another caused a differential down-regulation in CKI expression
in PHN. The expression for the CKI p15 and p27 waspossibility is that the levels of negative cell cycle proteins
(CKIs) increase. To address these possibilities, we stud- unchanged. In contrast, bFGF caused a marked and se-
lective decrease in p21 levels that coincided with in-ied the passive Heymann nephritis (PHN) model of
membranous nephropathy, which is induced by the ad- creased DNA synthesis. These results showed that the
increase in the CKIs p21 and p27 may be responsible forministration of an antibody to the anti-Fx1A antigen on
the GECs, resulting in a complement-dependent injury limiting DNA synthesis in the GECs following immune-
mediated injury and that lowering the levels of p21 wasto GECs [41, 42]. This is followed by the formation of
subepithelial immune deposits, foot process fusion and required for DNA synthesis.
To determine the functional role for p21 in GEC pro-effacement, and proteinuria. In contrast to the increase
in mesangial cell number following complement-induced liferation, experimental glomerulonephritis was induced
injury to the mesangial cell, the GEC number is normal in p21 knockout mice and control p21 wild-type mice
in experimental membranous nephropathy [43]. Studies (see Note Added in Proof, number 1). A striking finding
have shown that this is due to an apparent inability of was that GEC DNA synthesis was markedly increased
GECs to proliferate. The significance of the apparent in nephritic p212/2 mice compared with controls. More-
inability of GECs to proliferate has been proposed by over, GEC proliferation was also increased, and this
Kriz and Rennke [34, 39, 44] to involve the inability of was associated with increased matrix production and a
GECs to replace injured and lost GECs leading to a marked decline in renal function compared with controls.
denuded glomerular basement membrane, which under- Figure 4 summarizes our current thinking regarding
lies the development of progressive glomerulosclerosis. the role of CKI in GEC biology. GEC exit from the cell
To determine if the inability of GECs to proliferate cycle during glomerulogenesis coincides with the de novo
is due to the lack of cell cycle proteins required for DNA expression of the CKI p27 and p57. It is very tempting
synthesis, the expression for cyclin A and CDK2 was to speculate that these specific cell cycle proteins are
measured. Complement-dependent GEC injury in PHN required for GEC differentiation. In the mature quies-
was followed by a small but significant increase in immu- cent GEC, the levels of CKI determine the proliferative
nostaining for cyclin A and CDK2, and this localized to capacity of GECs rather than the inability of GECs to
GECs [45]. These results suggested that GECs have the increase and activate cell cycle proteins required for
“nuclear machinery” required for DNA synthesis and DNA synthesis. Thus, if the levels of p21 and p27 in-
that the apparent lack of proliferation was likely not crease in diseases such as membranous nephropathy,
entirely due to the inability to increase cyclin A and GECs do not proliferate. In contrast, if p21 or p27 levels
CDK2. decrease following injury, GECs re-engage the cell cycle
What about the role of CKIs in membranous nephrop- and undergo a marked increase in DNA synthesis and
athy? In contrast to a decrease in p27 levels in immune- proliferation.
mediated injury to mesangial cells in Thy1 [21], immune-
mediated injury to GECs in membranous nephropathy
GLOMERULAR HYPERTROPHYwas associated with a marked increase in immunostain-
In contrast to the marked mesangial cell proliferationing for the CKIs p21 and p27 [45]. Cell-type–specific
that follows many forms of immune- and nonimmune-markers showed that increased p21 and p27 staining lo-
mediated glomerular injury, the predominant growth re-calized to GECs. To show that these CKIs where respon-
sponse by the mesangial cell in diabetic nephropathy issible for limiting DNA synthesis in GECs, protein was
hypertrophy [48–50]. There is also a decrease in GECextracted from isolated glomeruli from PHN rats, and
number in human diabetic nephropathy [51].co-immunoprecipitation studies were performed. The re-
sults showed that there was an increase in the binding When a cell engages the cell cycle at the early G1
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Fig. 4. Proposed schema for visceral glomer-
ular epithelial cell (GEC) proliferation and
differentiation. During glomerulogenesis, pro-
liferating GECs exit from the cell cycle coin-
cides with the de novo expression of the cyclin
kinase inhibitors (CKI) p27 and p57 and the
development of a terminally differentiated
phenotype. The levels of CKI determine the
proliferative response of mature GECs to in-
jury. An increase in p21 and p27 maintains
a terminally differentiated phenotype where
GEC proliferation is limited. In contrast, low-
ering p21 and p27 levels is associated with a
dedifferentiated phenotype, which prolifer-
ates.
Fig. 5. Diabetic glomerular hypertrophy.
The proposed schema shows that diabetic glo-
merular hypertrophy is due to increased levels
of the cyclin kinase inhibitors p21 and p27.
Hyperglycemia increases p21 and p27 levels,
which block DNA synthesis in the setting
where protein is increased, thus leading to
hypertrophy (defined as an increase in protein
to DNA ratio). Reducing levels of these cyclin
kinase inhibitors attenuates diabetic glomeru-
lar hypertrophy, despite an increase in trans-
forming growth factor-b1.
phase, there is an increase in protein content. Because and A and CDK2 could not be detected in the rat [54]
and mouse [53] streptozotocin models of diabetic ne-of the absence of DNA synthesis during the G1 phase
of the cell cycle, the ratio of protein to DNA is physiolog- phropathy.
In contrast to the expression of cyclins and CDKs,ically increased (Fig. 1). Hypertrophy is defined as a
pathological increase in protein to DNA ratio [3, 52]. glucose-induced mesangial cell hypertrophy in vitro is
associated with a marked increase in levels for the CKIsThus, we and others have developed the hypothesis that
hypertrophy may be due to an increase in CKIs. p21 [53] and p27 [55]. Furthermore, Wolf et al showed
that lowering p27 levels with antisense oligonucleotidesWhy does mesangial cell hypertrophy predominate
rather than proliferation in diabetic nephropathy? To reduces glucose-induced hypertrophy in mesangial cells
in vitro [55]. Similar to cell culture studies, the expressiondetermine if this was due to a lack of cyclin and CDK
expression, studies were undertaken in cell culture and for both p21 [53] and p27 [55] is increased during glomer-
ular hypertrophy in the streptozotocin-induced model ofexperimental diabetic nephropathy. Glucose-induced
mesangial cell hypertrophy in vitro was not associated diabetic nephropathy, and p27 is also increased in the
db/db model of diabetic nephropathy [56].with an increase in levels for the late G1 (cyclin E) or S
phase (cyclin A) cell cycle proteins nor in their catalytic To determine if p21 is required for the development
of diabetic glomerular hypertrophy, streptozotocin waspartner CDK2 [53]. Similarly, an increase in cyclin E
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